NCT06379360View on ClinicalTrials.gov

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Hypomethylating agent, Azacitidine or Decitabine

All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER